Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies an observational study in Japan

Medicine (United States)

Volumn 94, Issue 4, 2015, Pages

  Watanabe, Yurika ^a   Suzuki, Shigeaki ^a   Nishimura, Hiroaki ^b,c   Murata, Ken Ya ^d   Kurashige, Takashi ^e   Ikawa, Masamichi ^f   Asahi, Masaru ^g   Konishi, Hirofumi ^h   Mitsuma, Satsuki ⁱ   Kawabata, Satoshi ^j   Suzuki, Norihiro ^a   Nishino, Ichizo ^b,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f UNIVERSITY OF FUKUI   (Japan)

^g MIE UNIVERSITY   (Japan)

^h UNIVERSITY OF TOYAMA   (Japan)

ⁱ CHIBA UNIVERSITY   (Japan)

^j ASAHIKAWA RED CROSS HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AUTOANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; SIGNAL RECOGNITION PARTICLE; AUTOANTIBODY; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; JAPAN; JAPANESE (PEOPLE); LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; MUSCLE CELL; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; BLOOD; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MIDDLE AGED; NECROSIS; NEUROLOGIC EXAMINATION; PATHOLOGY; SKELETAL MUSCLE;

AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS; NECROSIS; NEUROLOGIC EXAMINATION;

EID: 84938068295     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000416     Document Type: Article

References (25)

1. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014; 168:6-15.
2. de Sousa E, Howard J. More evidence for the association between statins and myasthenia gravis. Muscle Nerve. 2008; 38:1085-1086.
3. Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve. 2013; 48:477-483.
4. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011; 63:713-721.
5. Christopher-Stine L, Casciola-Rosen LA, Hong G., et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010; 62:2757-2766.
6. Drouot L, Allenbach Y, Jouen F. et al.: Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther. 2014; 16:R39.
7. Allenbach Y, Drouot L, Rigolet A., et al. Anti-HMGCR autoantibo-dies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore). 2014; 93:150-157.
8. Musset L, Miyara M, Benveniste O., et al. Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies. J Immunol Res. 2014405956.
9. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8:475-490.
10. Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet. 2002; 360:717.
11. Cartwright MS, Jeffery DR, Nuss G.R., et al. Statin-associated exacerbation of myasthenia gravis. Neurology. 2004; 63:2188.
12. Purvin V, Kawasaki A, Smith K.H., et al. Statin-associated myasthe-nia gravis: report of 4 cases and review of the literature. Medicine (Baltimore). 2006; 85:82-85.
13. Oh SJ, Dhall R, Young A., et al. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008; 38:1101-1107.
14. Elsais A, Lund C, Kerty E. Ptosis, diplopia and statins: an association? Eur J Neurol. 2008; 15:e92-e93.
15. Gale J, Danesh-Meyer HV. Statins can induce myasthenia gravis. J Clin Neurosci. 2014; 21:195-197.
16. Suzuki S, Yonekawa T, Kuwana M., et al. Clinical and histological findings associated with autoantibodies detected by RNA immuno-precipitation in inflammatory myopathies. J Neuroimmunol. 2014; 274:202-208.
17. Hoogendijk JE, Amato AA, Lecky B.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004; 14:337-345.
18. Hilton-Jones D, Miller A, Parton M., et al. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London 2008. Neuromuscul Disord. 2010; 20:142-147.
19. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000; 70:327-334.
20. Suzuki S, Utsugisawa K, Iwasa K., et al. Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis. J Neuroimmunol. 2011; 237:87-92.
21. Suzuki S, Satoh T, Yasuoka H., et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol. 2005; 170:141-149.
22. Suzuki S, Hayashi YK, Kuwana M, et al. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol. 2012; 69:728-732.
23. Gilhus NE. Is it safe to use statins in patients with myasthenia gravis? Nat Clin Pract Neurol. 2009; 5:8-9.
24. Klein R, Marx A, Strobel P., et al. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum Immunol. 2013; 74:1184-1193.
25. Mammen AL, Pak K, Williams E.K., et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken). 2012; 64:269-272.